Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia.

[1]  Domenico Di Carlo,et al.  Pretreatment HIV drug Resistance and Treatment Failure in Non-Italian HIV-1-Infected Patients Enrolled in ARCA , 2020, Antiviral therapy.

[2]  M. Giacomini,et al.  How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. , 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  U. Liebert,et al.  HIV-1C proviral DNA for detection of drug resistance mutations , 2018, PloS one.

[4]  F. Ceccherini‐Silberstein,et al.  Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  P. Arazo,et al.  Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment , 2018, Journal of acquired immune deficiency syndromes.

[6]  Diederick E Grobbee,et al.  Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. , 2017, The Lancet. Infectious diseases.

[7]  N. Funderburg,et al.  Inflammation, Immune Activation, and Antiretroviral Therapy in HIV , 2017, Current HIV/AIDS Reports.

[8]  R. Shafer,et al.  Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis , 2016, PloS one.

[9]  M. Huilcamán,et al.  Respuesta virológica e inmunológica a la terapia anti-retroviral en pacientes portadores de infección por VIH atendidos en una red de salud académica de Chile , 2016 .

[10]  L. Vandekerckhove,et al.  Drug Resistance is Rarely the Cause or Consequence of Long-Term Persistent Low-Level Viraemia in HIV-1-Infected Patients on ART , 2015, Antiviral therapy.

[11]  Jeffrey N. Martin,et al.  HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument , 2015, Antimicrobial Agents and Chemotherapy.

[12]  Thomas Lengauer,et al.  Proviral DNA as a Target for HIV-1 Resistance Analysis , 2015, Intervirology.

[13]  D. Katzenstein,et al.  HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program , 2015, PloS one.

[14]  J. Sterne,et al.  Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. , 2014, AIDS.

[15]  P. Harrigan,et al.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure , 2014, AIDS.

[16]  P. Harrigan,et al.  Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  F. Ceccherini‐Silberstein,et al.  Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Rafael Delgado.  [Detection of resistance mutations in proviral DNA in HIV-1 infection]. , 2013, Enfermedades infecciosas y microbiologia clinica.

[19]  J. Sánchez-Payá,et al.  Low-Level HIV Viremia Is Associated With Microbial Translocation and Inflammation , 2013, Journal of acquired immune deficiency syndromes.

[20]  E. Coakley,et al.  HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. , 2008, World journal of AIDS.

[21]  Jeffrey N. Martin,et al.  Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia , 2012, Antimicrobial Agents and Chemotherapy.

[22]  C. Delaugerre,et al.  Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients , 2012, PloS one.

[23]  D. Katzenstein,et al.  Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1. , 2012, Journal of AIDS & clinical research.

[24]  D. Kuritzkes,et al.  Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia , 2011, AIDS.

[25]  J. Yombi,et al.  HIV‐1 proviral resistance mutations: usefulness in clinical practice , 2010, HIV medicine.

[26]  Patricia Vásquez,et al.  [Prevalence of primary antiretroviral resistance among HIV infected patients in Chile]. , 2010, Revista medica de Chile.

[27]  A. Phillips,et al.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. , 2010, The Journal of infectious diseases.

[28]  N. Saksena,et al.  Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[29]  D. Kuritzkes,et al.  Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System , 2003, Journal of Clinical Microbiology.